Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis - Clinical Lymphoma, Myeloma and Leukemia clinical-lymphoma-myeloma-leukemia.com/article/S2152-… Report on pts after 2014 One half came off dialysis

Thanos Dimopoulos presenting ADC-based 2nd line options for RRMM at the 6th EMN meeting in Athens Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics EMN #EMN2025

Έναρξη Θεραπευτικών Εξελίξεων 2025 - 50ο έτος ! Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics Thanos Dimopoulos

Prof Terpos and Gavriatopoulou mgavriatopoulou presenting the updated EHA-EMN clinical guidelines 2025 for multiple myeloma at #EMN2025 in Athens ! Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics Thanos Dimopoulos EMN European Hematology Association

A big thank you to everyone who joined us at #EMN2025 in Athens! Insightful presentations, engaging sessions, and vibrant discussions. We’re already looking forward to continuing the momentum in beautiful Prague next year for #EMN2026, on 16–18 April 2026. See you there!

#Myeloma Paper of the Day: Yearly assessment of bone disease in patients w/ smoldering myeloma identifies early bony progression events in 9.7% of pts w/o biochemical PD and could be considered a standard clinical practice: pubmed.ncbi.nlm.nih.gov/40217676/. #mmsm

Νέα δημοσίευση για το Πολλαπλό Μυέλωμα στο κορυφαίο επιστημονικό περιοδικό New England Journal of Medicine με πρώτο συγγραφέα τον Διευθυντή της Θεραπευτικής Κλινικής ΕΚΠΑ Καθηγητή Θάνο Δημόπουλο! Thanos Dimopoulos

Melbourne in May on Amyloidosis Day! Great workshop with Stathis The Australian Amyloidosis Network patients’ association is now led by Maureen & Garry Mahon (took over from the great Pat Neely). Loved catching up with Brendan, Olga and James. Thank you.

Discontinuation of Len maint. 3 years post autoHCT with sustained BM and imaging MRD -ve status. N=52, 7-year PFS: 90%, 3-year treatment-free survival: 75.8% #mmsm #btsm Thanos Dimopoulos @BloodJournal ashpublications.org/blood/article/…

Now in @BloodJournal: congrats Thanos Dimopoulos et al on studying this prospectively! I love the abstract! Stopping len is a burning question for the #MMsm community and can also stop burning holes in our pocketbooks 💸 Good to see such great post-discontinuation PFS data here!

Not all advances meet our hopes. Birtamimab, an anti-amyloid fibril agent, did not improve survival in the AFFIRM-AL trial for Mayo Stage IV AL amyloidosis. A disappointing result—but a clear reminder of the need for continued progress. BU Amyloidosis Center

Sparing dexamethasone strategies for TI MM! #EHA2025

Just out: Mayo Clinic mSMART Risk Stratification of Myeloma #EHA25 1/ We recommend and use same high risk cytogenetic definition as the latest IMS/IMWG paper 2/ Primary plasma cell leukemia is high risk myeloma 3/ We define Double-hit high risk myeloma msmart.org/mm-treatment-g…

Prof Terpos and Gavriatopoulou mgavriatopoulou present the updated 2025 EHA-EMN Clinical Practice Guidelines for Multiple Myeloma Diagnosis, Treatment and Follow-up at the #EHA2025 #EHA in Milan ! Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics Thanos Dimopoulos

Dr Maria Gavriatopoulou mgavriatopoulou co-chairs with Dr Mattia D'Agostino Mattia D’Agostino the session on Novel Prognostic Features in Plasma Cell Disorders #EHA2025 Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics

Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

Prof Thanos Dimopoulos presented at #EHA2025 in Milan, the initial results from MagnetisMM-6 trial Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics

#Myeloma Paper of the Day: Revised renal stratification & progression model w/ 4-stages predicts long-term AL #amyloidosis outcomes; risk of PD to renal replacement increased in stages (Hazard ratio: 3.25, 5.13, 10.66 for Stages 2A, 2B & 3 vs. 1): pubmed.ncbi.nlm.nih.gov/40568719/. #mmsm

Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm nature.com/articles/s4157… European Hematology Association EMN Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics

Myeloma can be cured in some patients and these numbers will increase with current therapist onlinelibrary.wiley.com/doi/10.1002/aj…